RxDoctor Payments Data

Preyanka Aggarwal, MD

Family Medicine · Haines City, FLNPI 1205036647

Payments from drug & device makers

$2,105in general payments, 2019–2025

Across 103 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$386
  • Novo Nordisk$373
  • Exact Sciences$334
  • GSK$277
  • Lilly USA, LLC$203
  • Abbott$199
  • plus $333 from 7 others
$1,895in research payments, 2019–2025

Across 10 payments — averaging $189.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$2K

What the payments were for

  • Food & beverage$2,09199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,105 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$46,414
Medicare patients
204
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$51,498
MounjaroTirzepatide33$40,522
JanuviaSitagliptin Phosphate24$34,388
FarxigaDapagliflozin Propanediol34$33,160
RybelsusSemaglutide14$25,614
OzempicSemaglutide19$24,961
XareltoRivaroxaban23$23,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,507
Bydureon BciseExenatide Microspheres12$10,082
Atorvastatin Calcium540$6,026
Levothyroxine Sodium267$3,109
Albuterol Sulfate HfaAlbuterol Sulfate71$3,106
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,756
Losartan Potassium255$2,680
Telmisartan91$2,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$51,49842 claims
Novo NordiskRybelsus, Ozempic$373$50,57533 claims
Lilly USA, LLCMounjaro$203$40,52233 claims
AstraZenecaFarxiga$386$33,16034 claims
GSKTrelegy Ellipta$277$14,50714 claims
AbbVieSynthroid$19$1,15719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Haines City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →